Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 28 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )
Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

9 Customer Reviews

In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.
ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.
HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.
MEF cells were treated for 24 hours with the Bcl-2 antagonists Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.
Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot.

Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;TUmlEPTB;MD6wNFAxOzF5IN88US=>	NYnPNmw2W0GQR1XS
SK-MEL-30	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMECwN\|U2KM7:TR?=	NX3kOYxIW0GQR1XS
NALM-6	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7HSGF{UUN3ME2wMlAxODN3NjFOwG0>	MW\TRW5ITVJ?
KYSE-450	M4HE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vvNmlEPTB;MD6wNFA1PjlizszN	MkjjV2FPT0WU
BHY	M3;tRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[4cGlEPTB;MD6wNFA3ODFizszN	MmDMV2FPT0WU
GR-ST	NIDFZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMECwOlQ5KM7:TR?=	M2rVNXNCVkeHUh?=
786-0	M13s[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfkfphUUUN3ME2wMlAxODd5NjFOwG0>	M3jG[XNCVkeHUh?=
C-33-A	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMECwPFQ5KM7:TR?=	NH\UfGRUSU6JRWK=
BHT-101	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLXT2pKSzVyPUCuNFAyODZizszN	NH7LflJUSU6JRWK=
EB2	M3TPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnVeWFKSzVyPUCuNFAyOThizszN	MlvQV2FPT0WU
G-361	NVv4S41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHtVG5KSzVyPUCuNFAyOjRizszN	NWXQOHp3W0GQR1XS
KE-37	M3nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v0[GlEPTB;MD6wNFEzQCEQvF2=	MX;TRW5ITVJ?
MHH-PREB-1	NXzMVHlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn6N3JKSzVyPUCuNFAyPCEQvF2=	NHzDWotUSU6JRWK=
MCF7	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\kV2lEPTB;MD6wNFE2QSEQvF2=	MUDTRW5ITVJ?
LOUCY	NXnHRoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjROmdKSzVyPUCuNFAyPzVizszN	MoXxV2FPT0WU
EW-7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;wUnl1UUN3ME2wMlAxOTd3IN88US=>	MYHTRW5ITVJ?
KYSE-510	NIHHeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\jV2o2UUN3ME2wMlAxOjN\|IN88US=>	M3XL[nNCVkeHUh?=
SK-MEL-3	NIHBWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTiTWM2OD1yLkCwNlY1KM7:TR?=	NXjKd5ZIW0GQR1XS
HAL-01	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLKeJhKSzVyPUCuNFAzQTdizszN	M2fOdnNCVkeHUh?=
HCC2998	NYPET2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMECzN\|Uh\|ryP	MVTTRW5ITVJ?
A375	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XHO2lEPTB;MD6wNFM2KM7:TR?=	MkHBV2FPT0WU
MZ7-mel	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DqfWlEPTB;MD6wNFM6QSEQvF2=	MWLTRW5ITVJ?
SH-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO0TWM2OD1yLkCwOFE4KM7:TR?=	NUX4bmRuW0GQR1XS
HT-144	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMEC0N{DPxE1?	NHjWe2tUSU6JRWK=
KYSE-140	MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL2TWM2OD1yLkCwOFM2KM7:TR?=	NILGe2dUSU6JRWK=
PSN1	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITFUIxKSzVyPUCuNFA1PjdizszN	MkjPV2FPT0WU
COLO-679	NEPJO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojVTWM2OD1yLkCwOFk5KM7:TR?=	M3L5UXNCVkeHUh?=
SW620	NWq3WWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEC1NVEh\|ryP	M3\kXnNCVkeHUh?=
HGC-27	M{XUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPXTWM2OD1yLkCwOVI1KM7:TR?=	M2[1dnNCVkeHUh?=
IGROV-1	NGK4W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWriZVR1UUN3ME2wMlAxPiEQvF2=	MWfTRW5ITVJ?
IGR-1	NGfLV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TXc2lEPTB;MD6wNFYxOSEQvF2=	MYjTRW5ITVJ?
EW-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXSTWM2OD1yLkCwOlUyKM7:TR?=	M{jRfHNCVkeHUh?=
769-P	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLtZZJqUUN3ME2wMlAxPjd6IN88US=>	NWC3OmJmW0GQR1XS
HN	M2j0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXywRotHUUN3ME2wMlAxPjd7IN88US=>	NXvUNnlGW0GQR1XS
SIG-M5	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fjPGlEPTB;MD6wNFcyKM7:TR?=	M1K3ZXNCVkeHUh?=
IST-MEL1	M3;URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4izN2lEPTB;MD6wNFgyQCEQvF2=	MkXnV2FPT0WU
ST486	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDkTWM2OD1yLkCwPFI2KM7:TR?=	MWnTRW5ITVJ?
ES7	M{X3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWryfWVQUUN3ME2wMlAxQDR4IN88US=>	MlniV2FPT0WU
GAK	NHG4blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzIV2k4UUN3ME2wMlAxQDR6IN88US=>	NGrOWGxUSU6JRWK=
BB30-HNC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEC4OVgh\|ryP	M1fa[3NCVkeHUh?=
IPC-298	NX7aZWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvxe5BoUUN3ME2wMlAxQTJ5IN88US=>	Mo\6V2FPT0WU
NKM-1	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEC5O\|Ih\|ryP	M1LET3NCVkeHUh?=
RKO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn1TWM2OD1yLkCxNFQ1KM7:TR?=	NFvIRYFUSU6JRWK=
ACN	NXPLZ49uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXsTWM2OD1yLkCxNVMyKM7:TR?=	M4nBXHNCVkeHUh?=
SW1417	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:2eItKSzVyPUCuNFEzOjVizszN	M3OzNnNCVkeHUh?=
SR	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3sR5lKSzVyPUCuNFEzOzVizszN	M{fzcnNCVkeHUh?=
SNG-M	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjNTWM2OD1yLkCxN\|E4KM7:TR?=	MWLTRW5ITVJ?
CAL-12T	NXfFb4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrTfmhKSzVyPUCuNFE{PDZizszN	MYrTRW5ITVJ?
HSC-3	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37pe2lEPTB;MD6wNVM2PSEQvF2=	NIi3T3JUSU6JRWK=
DOHH-2	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\MTWM2OD1yLkCxOFEzKM7:TR?=	MoTNV2FPT0WU
NB69	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHPW2JKSzVyPUCuNFE2PjVizszN	NVzhSFVVW0GQR1XS
LC-2-ad	M{TlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPmTWM2OD1yLkCxOVgyKM7:TR?=	MWnTRW5ITVJ?
RVH-421	NIPPXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETCW\|ZKSzVyPUCuNFE3PzRizszN	Mk\PV2FPT0WU
TGW	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDBTWM2OD1yLkCxO\|M6KM7:TR?=	MXPTRW5ITVJ?
HCC1569	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HnemlEPTB;MD6wNVc6PyEQvF2=	NGHPNndUSU6JRWK=
CAL-85-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M170bmlEPTB;MD6wNVg{OiEQvF2=	MULTRW5ITVJ?
RPMI-8402	NX;ad2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;jTWM2OD1yLkCxPFU5KM7:TR?=	MUTTRW5ITVJ?
THP-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEG5PVgh\|ryP	NV23ZWh1W0GQR1XS
ONS-76	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHjPGtCUUN3ME2wMlAzODN4IN88US=>	MX3TRW5ITVJ?
A2780	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX72UFBUUUN3ME2wMlAzODd7IN88US=>	NUfDVJZwW0GQR1XS
RPMI-2650	NH;tbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMEKyPVYh\|ryP	MV;TRW5ITVJ?
MEL-HO	M4TrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMEKzOFgh\|ryP	M2DzPHNCVkeHUh?=
MC-CAR	M4LP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jueGlEPTB;MD6wNlM2PiEQvF2=	M{KzbHNCVkeHUh?=
HSC-2	M1z6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\KTWM2OD1yLkCyOFY3KM7:TR?=	MVLTRW5ITVJ?
MEL-JUSO	NGrhNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPXTWM2OD1yLkCyOFc{KM7:TR?=	MWHTRW5ITVJ?
CAL-62	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfuTWM2OD1yLkCyOlAzKM7:TR?=	NHHoTVJUSU6JRWK=
DMS-273	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DMSGlEPTB;MD6wNlg1PyEQvF2=	MVTTRW5ITVJ?
S-117	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjEXXV5UUN3ME2wMlAzQTB4IN88US=>	MoLEV2FPT0WU
SUP-T1	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHQVVJKSzVyPUCuNFI6PDlizszN	NG\McmxUSU6JRWK=
MZ2-MEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDjXmFrUUN3ME2wMlAzQTV7IN88US=>	NInkd4VUSU6JRWK=
KYSE-270	M1vnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfoTWM2OD1yLkCyPVc3KM7:TR?=	NUe4PJU3W0GQR1XS
CMK	M1jqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEOwNlMh\|ryP	NFfnVVdUSU6JRWK=
8505C	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVW1d45WUUN3ME2wMlA{ODRizszN	Mn;QV2FPT0WU
NUGC-3	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX1[ZVKSzVyPUCuNFMxPDhizszN	NIDyUVhUSU6JRWK=
A101D	NIKwOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvjTWM2OD1yLkCzNFU2KM7:TR?=	MWTTRW5ITVJ?
G-401	M2fNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEOwPVMh\|ryP	NUPVXnB4W0GQR1XS
OVCAR-8	M{LpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TwbmlEPTB;MD6wN\|ExPyEQvF2=	MlfIV2FPT0WU
IMR-5	NGS5NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DvVWlEPTB;MD6wN\|I1PCEQvF2=	NGftNW1USU6JRWK=
DoTc2-4510	M1rPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTB[VRHUUN3ME2wMlA{Ozl\|IN88US=>	MXjTRW5ITVJ?
HOS	M33ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMEO0O\|Mh\|ryP	NHHMcVNUSU6JRWK=
HEC-1	NVXoXlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:zd4VKSzVyPUCuNFM3QCEQvF2=	M4jSbnNCVkeHUh?=
SW756	NF\P[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEO4NlEh\|ryP	NV\vfmVqW0GQR1XS
NCI-H64	NF\4Z4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMEO4OFIh\|ryP	MnPBV2FPT0WU
EW-16	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\VTWM2OD1yLkCzPVA6KM7:TR?=	NHzWWY9USU6JRWK=
CAL-51	NGTwZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMESwNFUh\|ryP	NFPFNmJUSU6JRWK=
KYSE-150	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vJU2lEPTB;MD6wOFAyOSEQvF2=	MV3TRW5ITVJ?
SW1710	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz1cVdKSzVyPUCuNFQxOThizszN	MUfTRW5ITVJ?
HuP-T4	NF76W\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\MSGhKUUN3ME2wMlA1OTF6IN88US=>	M2frfnNCVkeHUh?=
LB373-MEL-D	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOzOJkxUUN3ME2wMlA1OjN{IN88US=>	M2fsTXNCVkeHUh?=
EW-13	M{XvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rjWWlEPTB;MD6wOFQxPiEQvF2=	MXLTRW5ITVJ?
HT-29	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfITWM2OD1yLkC0OFkh\|ryP	MXrTRW5ITVJ?
SCC-25	NUK1cm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vS[mlEPTB;MD6wOFQ6PCEQvF2=	NHXiZpFUSU6JRWK=
REH	M2LZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7pWVJ{UUN3ME2wMlA1PjN3IN88US=>	M1TFUnNCVkeHUh?=
L-363	NX;FW\|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMES2O\|kh\|ryP	MlnaV2FPT0WU
NCI-H1770	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHwTWM2OD1yLkC0Olk4KM7:TR?=	MXvTRW5ITVJ?
CHL-1	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjUO5A4UUN3ME2wMlA1QDV5IN88US=>	NXHXXZBbW0GQR1XS
ES1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMES4PFUh\|ryP	NIrMdmNUSU6JRWK=
SCC-15	M{DxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3OTWM2OD1yLkC0PVAzKM7:TR?=	NYHlWpAxW0GQR1XS
MRK-nu-1	M2DpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPFTWM2OD1yLkC0PVM3KM7:TR?=	NVH1[nE4W0GQR1XS
PF-382	M1fIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\rUGx1UUN3ME2wMlA1QTN7IN88US=>	M4nFUHNCVkeHUh?=
COLO-680N	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DnTmlEPTB;MD6wOVA1PyEQvF2=	NWHSc412W0GQR1XS
LK-2	M1jWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXPfYVLUUN3ME2wMlA2ODZ\|IN88US=>	NH3LVGdUSU6JRWK=
NCI-H2342	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr4UHNKSzVyPUCuNFUyOTdizszN	NFvKd4hUSU6JRWK=
HMV-II	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEWyN\|kh\|ryP	M3rxdHNCVkeHUh?=
PC-14	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zIdGlEPTB;MD6wOVI2OiEQvF2=	MluwV2FPT0WU
COLO-320-HSR	NELZdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TiNWlEPTB;MD6wOVI5QSEQvF2=	NEHQeodUSU6JRWK=
697	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLITWM2OD1yLkC1N\|I{KM7:TR?=	MlPaV2FPT0WU
NEC8	M{XXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XrRmlEPTB;MD6wOVU6KM7:TR?=	M2nxc3NCVkeHUh?=
LCLC-97TM1	M2nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULGWZlvUUN3ME2wMlA2PTl2IN88US=>	MkPYV2FPT0WU
Daoy	NHzZW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnqXlVKSzVyPUCuNFU3OTZizszN	M4CzeXNCVkeHUh?=
ETK-1	M{n6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMEW2O\|Ih\|ryP	NG\iU5dUSU6JRWK=
A388	NX:3bJY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;WOGlEPTB;MD6wOVY6PSEQvF2=	M{L4e3NCVkeHUh?=
COLO-205	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVyw[m16UUN3ME2wMlA2PzF4IN88US=>	NFTBeZFUSU6JRWK=
SK-PN-DW	NHvObZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEi3UJlKSzVyPUCuNFU4OjlizszN	NIfpNY1USU6JRWK=
SF268	NVPQO2dLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NET1do5KSzVyPUCuNFU4PTZizszN	MkfFV2FPT0WU
OCI-AML2	M2rqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj1dINKSzVyPUCuNFU4PzdizszN	MXHTRW5ITVJ?
GAMG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMEW4JO69VQ>?	NGm3S21USU6JRWK=
BCPAP	M{i3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEW4PVIh\|ryP	NFnLXGlUSU6JRWK=
BC-1	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwME[wNlIh\|ryP	Mn7HV2FPT0WU
IA-LM	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjIZ4xKSzVyPUCuNFYxPTNizszN	MVLTRW5ITVJ?
NCI-H1299	NY\mW2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\v[GpDUUN3ME2wMlA3OTNizszN	NHO4OW9USU6JRWK=
COR-L23	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPNcFdKSzVyPUCuNFYyOzRizszN	NFLSdplUSU6JRWK=
KYSE-180	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHUc\|BKSzVyPUCuNFYyPDJizszN	M2rFVnNCVkeHUh?=
LOXIMVI	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3vTWM2OD1yLkC2NVg5KM7:TR?=	M3zHVXNCVkeHUh?=
BL-41	M{f5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwME[yNVkh\|ryP	M2LX[3NCVkeHUh?=
BL-70	NGPjVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL6TWM2OD1yLkC2N\|AzKM7:TR?=	NVjKVFBKW0GQR1XS
NOS-1	M4S2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHviVG1KSzVyPUCuNFY1OTFizszN	MYrTRW5ITVJ?
NB13	NXizN2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfMPHI{UUN3ME2wMlA3PDJzIN88US=>	M3ftTnNCVkeHUh?=
CAL-27	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwME[0OlQh\|ryP	NXHwcpFkW0GQR1XS
CA46	NG\nR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr5N2RKSzVyPUCuNFY2OzdizszN	NHThcIpUSU6JRWK=
SW962	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M121UGlEPTB;MD6wOlU3QSEQvF2=	MWnTRW5ITVJ?
NCI-H226	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfM[YxuUUN3ME2wMlA3PjN{IN88US=>	NUTzSnlbW0GQR1XS
KYSE-70	NXXhVpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwME[5OFUh\|ryP	M4\tdHNCVkeHUh?=
Daudi	NFfIdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEewPFEh\|ryP	MlPlV2FPT0WU
SW626	NWPKWW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMEeyNFQh\|ryP	M4H6cXNCVkeHUh?=
ESS-1	M3r4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkOxTWM2OD1yLkC3NlQ3KM7:TR?=	M1PGcXNCVkeHUh?=
YT	NYnUNHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEezOFUh\|ryP	Mn7mV2FPT0WU
P12-ICHIKAWA	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TBTmlEPTB;MD6wO\|M1QSEQvF2=	Mnu3V2FPT0WU
BxPC-3	M4\vdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH6T4RKSzVyPUCuNFc1PThizszN	MkD0V2FPT0WU
CTV-1	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVz4PFlYUUN3ME2wMlA4PTF5IN88US=>	NILabHNUSU6JRWK=
MLMA	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlOwTWM2OD1yLkC3OVM1KM7:TR?=	NIG5OYdUSU6JRWK=
WSU-NHL	NWrZd2o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvJUVZnUUN3ME2wMlA4PTV2IN88US=>	NFK3VmVUSU6JRWK=
CTB-1	NXS4elFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDZTWM2OD1yLkC3OVg5KM7:TR?=	NW\hWFZiW0GQR1XS
MMAC-SF	M4e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf2emJbUUN3ME2wMlA4PjZ6IN88US=>	M1fMcXNCVkeHUh?=
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLpfWFmUUN3ME2wMlA4QDBzIN88US=>	MkPkV2FPT0WU
NCI-H358	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDjdnNiUUN3ME2wMlA4QDd7IN88US=>	NXe0V3VYW0GQR1XS
BFTC-905	NE[0XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTmU3FKSzVyPUCuNFc6ODlizszN	NIXYTY5USU6JRWK=
NCI-H727	NEHY[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\ydmlEPTB;MD6wPFA2OyEQvF2=	MVzTRW5ITVJ?
CHP-212	NHXVOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInmcWxKSzVyPUCuNFgxQTVizszN	M4PNdXNCVkeHUh?=
HOP-62	NH[4V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfCN2Z2UUN3ME2wMlA5OjR3IN88US=>	Ml;3V2FPT0WU
CESS	NHrWRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7EbVlKSzVyPUCuNFgzPjlizszN	NV6zT5kyW0GQR1XS
HuCCT1	NHfZV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv0dXhKSzVyPUCuNFg{OzNizszN	MWXTRW5ITVJ?
DEL	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4X1PGlEPTB;MD6wPFM1PyEQvF2=	M1roUHNCVkeHUh?=
5637	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW1TWM2OD1yLkC4N\|Y4KM7:TR?=	MYHTRW5ITVJ?
RS4-11	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEi0PVch\|ryP	NXHD[XVYW0GQR1XS
KURAMOCHI	NGjYVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMEi1NFkh\|ryP	NIjhWIxUSU6JRWK=
A427	NVzuS\|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\4XYRKSzVyPUCuNFg2OTJizszN	NXjOdHpkW0GQR1XS
A3-KAW	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfhXXl2UUN3ME2wMlA5PTZ4IN88US=>	NITDTnZUSU6JRWK=
LS-123	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMEi3NVkh\|ryP	MX3TRW5ITVJ?
LoVo	NH7FRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMEi3NkDPxE1?	NXjLfJNiW0GQR1XS
PA-1	NVO5SJQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTxcJVmUUN3ME2wMlA5PzZ7IN88US=>	NXS4eYtjW0GQR1XS
CP50-MEL-B	M1rPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPHTWM2OD1yLkC4O\|k{KM7:TR?=	MVTTRW5ITVJ?
A431	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMEi4NFEh\|ryP	NGqySmdUSU6JRWK=
HCT-116	MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEi4NFIh\|ryP	NYPLTXVjW0GQR1XS
A4-Fuk	NFjLO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHMTWM2OD1yLkC4PVQ4KM7:TR?=	NUn5VG1MW0GQR1XS
RPMI-6666	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHWTWM2OD1yLkC4PVY4KM7:TR?=	Mmr0V2FPT0WU
Calu-6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXHcGhiUUN3ME2wMlA6ODJ7IN88US=>	NYjvUG54W0GQR1XS
KMOE-2	M3HhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX1Z5BJUUN3ME2wMlA6ODN7IN88US=>	NXLLS5N[W0GQR1XS
A704	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LDdWlEPTB;MD6wPVE2KM7:TR?=	NYDGXnM2W0GQR1XS
HO-1-N-1	NFvVd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPHXIhxUUN3ME2wMlA6OjR7IN88US=>	NX;weHJRW0GQR1XS
NCI-H2122	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLlTWM2OD1yLkC5N\|c5KM7:TR?=	NFe2eGpUSU6JRWK=
U-698-M	NX34ellIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[xNIRKSzVyPUCuNFk1ODlizszN	NFvuRZNUSU6JRWK=
IST-SL2	NGDvUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf3fZdKSzVyPUCuNFk1PjhizszN	M4f3UHNCVkeHUh?=
TE-10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTQTWM2OD1yLkC5OVg1KM7:TR?=	NF7WZ4NUSU6JRWK=
PANC-03-27	NFfyZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETTOnBKSzVyPUCuNFk3PzFizszN	NULoNVFKW0GQR1XS
KYSE-410	NYWzTHdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PXOWlEPTB;MD6wPVc6PyEQvF2=	NYf0SYtuW0GQR1XS
TE-8	M{\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOxZ4hKSzVyPUCuNFk5QDVizszN	MVHTRW5ITVJ?
MN-60	NGroOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\hOHVbUUN3ME2wMlA6QDl5IN88US=>	MYrTRW5ITVJ?
NCI-H460	M336VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED1WolKSzVyPUCuNVAxQSEQvF2=	NFS5c4VUSU6JRWK=
LB771-HNC	NGi0UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLYOYt[UUN3ME2wMlExOjV3IN88US=>	MWXTRW5ITVJ?
ES4	NFXtVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fjbmlEPTB;MD6xNFI3PCEQvF2=	M{nhRXNCVkeHUh?=
HUTU-80	NVTsVIJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nDZWlEPTB;MD6xNFM3PSEQvF2=	MWDTRW5ITVJ?
647-V	M4POO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfSN3ZNUUN3ME2wMlExPDB6IN88US=>	NYO2d3R5W0GQR1XS
HTC-C3	NUDldYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMUC0N\|Ih\|ryP	MnrNV2FPT0WU
NTERA-S-cl-D1	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T6ZmlEPTB;MD6xNFQ1QCEQvF2=	M17pSXNCVkeHUh?=
A2058	NFXS[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzqUXNKSzVyPUCuNVA3PTVizszN	MVfTRW5ITVJ?
MZ1-PC	M2rS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMUC4N{DPxE1?	NHr2[XVUSU6JRWK=
J82	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPu[HRKSzVyPUCuNVA5QDRizszN	NGjWPYZUSU6JRWK=
ARH-77	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z0O2lEPTB;MD6xNUDPxE1?	NF;yb3lUSU6JRWK=
Ca9-22	NILYR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTDZopSUUN3ME2wMlEyOTJ6IN88US=>	M{X1WXNCVkeHUh?=
NCI-H1648	NGKzfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XDUmlEPTB;MD6xNVI5PiEQvF2=	NHXjO2dUSU6JRWK=
MC116	NGW2T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETwb\|FKSzVyPUCuNVE{OzdizszN	MlfXV2FPT0WU
EoL-1-cell	M1PCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUiwZWY3UUN3ME2wMlEyPDZ5IN88US=>	M4jRcXNCVkeHUh?=
PANC-10-05	NEHCN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMUG0PVEh\|ryP	Mnv0V2FPT0WU
SF539	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILaNo5KSzVyPUCuNVE3OTZizszN	M1PxUnNCVkeHUh?=
ES8	NXOyTZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\3N5pOUUN3ME2wMlEyPjN\|IN88US=>	NYDLO2xFW0GQR1XS
NCI-H810	NYDLb4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4L5NWlEPTB;MD6xNVY3PCEQvF2=	NYfN[3l[W0GQR1XS
J-RT3-T3-5	M{jPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMUG3OUDPxE1?	MYDTRW5ITVJ?
NY	NVqzVoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DvdGlEPTB;MD6xNVgyPyEQvF2=	Mn3IV2FPT0WU
NCI-SNU-1	NG\ESIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMUKxOFgh\|ryP	NYnCW\|JPW0GQR1XS
EFM-19	M1nhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrrVJV3UUN3ME2wMlEzOzd2IN88US=>	MojhV2FPT0WU
HCC1806	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXmwOFhVUUN3ME2wMlEzOzh\|IN88US=>	NIq2TllUSU6JRWK=
HCE-T	M{TpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPh[llKSzVyPUCuNVI2OzFizszN	M1flOHNCVkeHUh?=
HT-1376	M3zFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DLUWlEPTB;MD6xNlY3QCEQvF2=	M2G3XXNCVkeHUh?=
BE-13	M1;5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PXdmlEPTB;MD6xNlg3PiEQvF2=	M1TzbHNCVkeHUh?=
NCI-H520	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;Lcm9KSzVyPUCuNVI5PjdizszN	NVqyXY1XW0GQR1XS
SK-MES-1	M4GxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfNVlRPUUN3ME2wMlEzQTF\|IN88US=>	NYnZWXlUW0GQR1XS
SNU-423	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfKTWM2OD1yLkGyPVE1KM7:TR?=	M13HZXNCVkeHUh?=
Ramos-2G6-4C10	NGDEU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zvcGlEPTB;MD6xNlkyPiEQvF2=	MoPNV2FPT0WU
EW-18	NFru[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:wTWM2OD1yLkGzNFI3KM7:TR?=	MXHTRW5ITVJ?
NCI-H2087	NWPybGU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj5bJpKSzVyPUCuNVMxOjdizszN	M2XsZnNCVkeHUh?=
COLO-792	NWnyN3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMUOxOlUh\|ryP	NWH0cWlPW0GQR1XS
QIMR-WIL	NEnFSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrhfFdXUUN3ME2wMlE{OjJ\|IN88US=>	NIjTUItUSU6JRWK=
ACHN	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLnTWM2OD1yLkGzNlQ4KM7:TR?=	NUn2UJJSW0GQR1XS
RPMI-8866	NVyxUpF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHoTWM2OD1yLkGzNlYyKM7:TR?=	NX7WVmpzW0GQR1XS
SK-LU-1	NYSxWWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMUO0OFkh\|ryP	MVfTRW5ITVJ?
SK-UT-1	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPjZ5NKSzVyPUCuNVM3OjhizszN	NFTVXnpUSU6JRWK=
MFE-296	NH\aSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUO4OlQh\|ryP	NGLYR49USU6JRWK=
RD	NFHJeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fMcmlEPTB;MD6xN\|k6PyEQvF2=	M{TGbHNCVkeHUh?=
LS-411N	M17ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\UbVNbUUN3ME2wMlE1Ojl3IN88US=>	MVLTRW5ITVJ?
NCI-H747	NFzjW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz4SYVnUUN3ME2wMlE1OyEQvF2=	NWjxZpVnW0GQR1XS
ES6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLoT5NKSzVyPUCuNVQ{PiEQvF2=	M3mwUXNCVkeHUh?=
TE-1	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHTTWM2OD1yLkG0OFA4KM7:TR?=	NXL6N3VqW0GQR1XS
SJSA-1	NVX2NVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPyTWM2OD1yLkG0O\|A4KM7:TR?=	MUPTRW5ITVJ?
NCI-H1355	M{TTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T4SmlEPTB;MD6xOVI6OyEQvF2=	NYK0SJBKW0GQR1XS
HEL	M3HRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHETHFKSzVyPUCuNVU1PDdizszN	NFjOb\|ZUSU6JRWK=
639-V	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLnTWM2OD1yLkG1OVk3KM7:TR?=	M4CwdXNCVkeHUh?=
AN3-CA	NFizXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLTd3FKSzVyPUCuNVU3OzlizszN	MUDTRW5ITVJ?
SK-MEL-2	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjP[GlKSzVyPUCuNVU3PjhizszN	M4LTN3NCVkeHUh?=
SW872	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXywcoVDUUN3ME2wMlE3ODR{IN88US=>	MVrTRW5ITVJ?
DU-4475	M1PPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;NS21PUUN3ME2wMlE3OTZ{IN88US=>	Mn\oV2FPT0WU
YKG-1	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q4VWlEPTB;MD6xOlI4OyEQvF2=	NEjDR4pUSU6JRWK=
GT3TKB	NIHmb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TiVGlEPTB;MD6xOlI5OyEQvF2=	M1;lZXNCVkeHUh?=
GB-1	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMU[0NlQh\|ryP	M3z4SXNCVkeHUh?=
KARPAS-422	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMU[1O\|Qh\|ryP	M4DHPXNCVkeHUh?=
ATN-1	NV[zUJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMU[2OVYh\|ryP	NH;pTHhUSU6JRWK=
HLE	NV\k[HRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXqZppKSzVyPUCuNVY5PzdizszN	M{f3PXNCVkeHUh?=
D-542MG	M{myTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTzNGl7UUN3ME2wMlE3QTh4IN88US=>	NY[wR4t2W0GQR1XS
EB-3	NEjHZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\QcGlEPTB;MD6xO\|MyKM7:TR?=	M37nOHNCVkeHUh?=
HCC1143	NFPndYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMUezPVYh\|ryP	NFTMWFJUSU6JRWK=
DJM-1	NX;mS3BiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV34NplrUUN3ME2wMlE4PDVzIN88US=>	NYPUclR7W0GQR1XS
BT-474	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\vc4RqUUN3ME2wMlE4PDh7IN88US=>	MYXTRW5ITVJ?
BB65-RCC	NEDV[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXOTWM2OD1yLkG3OVQ2KM7:TR?=	NXzIbGZbW0GQR1XS
NCI-H292	M{P2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMUe2NFEh\|ryP	MnnDV2FPT0WU
MKN28	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzweplKSzVyPUCuNVc3PTNizszN	NVH2VIxPW0GQR1XS
TK10	M{jUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGmzWFhKSzVyPUCuNVc4ODJizszN	MmroV2FPT0WU
TYK-nu	M3X6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHQNGxKSzVyPUCuNVc6PDlizszN	NWDFeI5pW0GQR1XS
8305C	M2XPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMUe5O\|Eh\|ryP	MorrV2FPT0WU
MV-4-11	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHGeYlKSzVyPUCuNVc6PzdizszN	MnLoV2FPT0WU
NCI-H522	M{PDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXydYJKSzVyPUCuNVgxQTRizszN	MlXJV2FPT0WU
Hs-578-T	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3YTWM2OD1yLkG4NlkzKM7:TR?=	MlPvV2FPT0WU
LCLC-103H	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLOcXVsUUN3ME2wMlE5PTJ5IN88US=>	NGPPRmpUSU6JRWK=
MHH-ES-1	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnL3TWM2OD1yLkG4OlI6KM7:TR?=	MknJV2FPT0WU
NCI-H441	M1qy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYexWW5xUUN3ME2wMlE6OTR6IN88US=>	NX\lR5czW0GQR1XS
AM-38	NF3xZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfnTWM2OD1yLkG5NlI2KM7:TR?=	NYnRZ4h2W0GQR1XS
SW1783	NGDQZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTJdnh2UUN3ME2wMlE6OzB3IN88US=>	MmW0V2FPT0WU
SK-HEP-1	NXjnR29jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof1TWM2OD1yLkG5OlM4KM7:TR?=	NEezVW9USU6JRWK=
OAW-28	NHrweWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jCR2lEPTB;MD6yNFE4QCEQvF2=	MUjTRW5ITVJ?
TE-15	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMkCyOVIh\|ryP	NIrSRXJUSU6JRWK=
HCE-4	NHzkZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMkCyPFQh\|ryP	MWjTRW5ITVJ?
JiyoyeP-2003	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHWNm9wUUN3ME2wMlIxOzN4IN88US=>	MkPmV2FPT0WU
OVCAR-4	NUfCT\|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzUTWM2OD1yLkKwOlI5KM7:TR?=	NUnmZodLW0GQR1XS
SNU-449	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfSTWM2OD1yLkKwO\|k4KM7:TR?=	MVPTRW5ITVJ?
SBC-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD4XYdzUUN3ME2wMlIyOjF3IN88US=>	M2nzS3NCVkeHUh?=
T84	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMkGyOFgh\|ryP	Mn\lV2FPT0WU
LP-1	NF2zXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvhbXEzUUN3ME2wMlIyOzB{IN88US=>	NH;0NFJUSU6JRWK=
MG-63	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3foOGlEPTB;MD6yNVM5OiEQvF2=	Mk\jV2FPT0WU
OAW-42	M2j6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTtTWM2OD1yLkKxOFc5KM7:TR?=	NXjIeow2W0GQR1XS
L-540	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrvPZFvUUN3ME2wMlIyPTl6IN88US=>	NILUNYNUSU6JRWK=
RH-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TaTGlEPTB;MD6yNlI1OiEQvF2=	M4ewV3NCVkeHUh?=
HCT-15	M3vpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMkK0PFQh\|ryP	M1jOOnNCVkeHUh?=
OCUB-M	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVyzdYM{UUN3ME2wMlIzPDh6IN88US=>	NHPCXpRUSU6JRWK=
GP5d	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17NfWlEPTB;MD6yNlUzQCEQvF2=	NWHk[3c1W0GQR1XS
NCI-H2030	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMkK3N\|Qh\|ryP	MkHNV2FPT0WU
ML-2	NGTSXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMkK4PFkh\|ryP	M{TnUHNCVkeHUh?=
CAL-39	NV;OSIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS2dWlKSzVyPUCuNlI6OzZizszN	NWnkWoZqW0GQR1XS
MIA-PaCa-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMkOyPFch\|ryP	MU\TRW5ITVJ?
TE-9	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMkOzNkDPxE1?	MoWxV2FPT0WU
LB2518-MEL	M2m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzwdJNKSzVyPUCuNlM{PzJizszN	MoLJV2FPT0WU
DB	M1P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXjRWJ5UUN3ME2wMlI{PDN6IN88US=>	NETtV4FUSU6JRWK=
NCI-H596	NEezUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPUUI9KSzVyPUCuNlM2PzFizszN	NIq4Z3lUSU6JRWK=
SW1990	NYjEeo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP4R4lKSzVyPUCuNlM6PDZizszN	NUPuOFFRW0GQR1XS
P30-OHK	M4rWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjIZnJ3UUN3ME2wMlI1ODVizszN	NIX2emlUSU6JRWK=
ALL-PO	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVi4RY5DUUN3ME2wMlI1OTZ7IN88US=>	M2foUHNCVkeHUh?=
Saos-2	NWP5UWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nJW2lEPTB;MD6yOFU4OSEQvF2=	M1z2NHNCVkeHUh?=
MFH-ino	NYfGdW1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEm3T4tKSzVyPUCuNlQ3QTJizszN	Moq0V2FPT0WU
OE33	NWm2WVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlO4TWM2OD1yLkK1NVEh\|ryP	NF3NbINUSU6JRWK=
Calu-3	NWDNfVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnXT2xKSzVyPUCuNlUzQTdizszN	MYDTRW5ITVJ?
HT	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\5RWZKUUN3ME2wMlI2PjJzIN88US=>	MlSzV2FPT0WU
LXF-289	NWS3RmtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHVPZJKSzVyPUCuNlU6QDRizszN	NXfzT3ZVW0GQR1XS
KGN	NUP2V2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMk[wPFkh\|ryP	MVPTRW5ITVJ?
NCI-H1417	M1HLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLtUVBEUUN3ME2wMlI3PTJ2IN88US=>	M1qxTXNCVkeHUh?=
SF126	NH;KbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGGycnJKSzVyPUCuNlc{ODJizszN	MmXGV2FPT0WU
SAS	NVzxdHdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMkezNFgh\|ryP	MkDkV2FPT0WU
22RV1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\oSmdJUUN3ME2wMlI4Ozd6IN88US=>	MWjTRW5ITVJ?
GI-1	NVvxNml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVywWYx5UUN3ME2wMlI4PDh5IN88US=>	Mo\EV2FPT0WU
ES3	NELx[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjMenVKSzVyPUCuNlc4PjNizszN	M2fRVnNCVkeHUh?=
NB1	M2riUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\Ed\|BNUUN3ME2wMlI4QDd4IN88US=>	NF\ySI1USU6JRWK=
NCI-H650	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrVZ5FKSzVyPUCuNlg{ODJizszN	MYTTRW5ITVJ?
IST-MES1	M2Htd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i3WWlEPTB;MD6yPFU2PCEQvF2=	MXvTRW5ITVJ?
UM-UC-3	M{X1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjGTGtKSzVyPUCuNlkyPCEQvF2=	MUnTRW5ITVJ?
CAL-120	NH;3d\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMkm2N\|Eh\|ryP	M1PGcXNCVkeHUh?=
UACC-62	M1PZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTLU4hKSzVyPUCuN\|AzPDFizszN	NX3Tb4djW0GQR1XS
TE-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrMZVNKSzVyPUCuN\|AzPDlizszN	NXy3cWtXW0GQR1XS
MKN1	NYXpSXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XlUWlEPTB;MD6zNFM3KM7:TR?=	Ml7lV2FPT0WU
KS-1	NXnPVYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zSO2lEPTB;MD6zNFUzPiEQvF2=	MkG2V2FPT0WU
GCIY	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwM{GwNFIh\|ryP	MUjTRW5ITVJ?
OVCAR-5	NWnDTZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC2TWM2OD1yLkOxNVA3KM7:TR?=	M{nLS3NCVkeHUh?=
U-266	NFvp[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwM{GxOFch\|ryP	MXXTRW5ITVJ?
Calu-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\VbWlEPTB;MD6zNVI5QSEQvF2=	NVy0WFdEW0GQR1XS
SK-LMS-1	NY\vb4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvhTWM2OD1yLkOxOFI6KM7:TR?=	MYDTRW5ITVJ?
COLO-741	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vucmlEPTB;MD6zNVYyPCEQvF2=	MmPGV2FPT0WU
RPMI-8226	NH\pSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m3OGlEPTB;MD6zNVY1OSEQvF2=	NYXIR3ZUW0GQR1XS
KM12	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jz[2lEPTB;MD6zNVg{KM7:TR?=	MlrvV2FPT0WU
NMC-G1	M4T1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwM{G4OkDPxE1?	NF3JWVhUSU6JRWK=
SJRH30	NYXVdIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXud2lKSzVyPUCuN\|IxPTJizszN	M2TFRXNCVkeHUh?=
COR-L105	M2m4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwM{KyNVgh\|ryP	M1H4bXNCVkeHUh?=
IM-9	NV[yTWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwM{OwNlEh\|ryP	M4PVc3NCVkeHUh?=
TE-12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1z6OmlEPTB;MD6zN\|MyPyEQvF2=	NH\EWlVUSU6JRWK=
KG-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwM{O0N\|Ih\|ryP	MWDTRW5ITVJ?
U251	M3njTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwM{O0OVYh\|ryP	MkexV2FPT0WU
EFO-27	NYLEbFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISxVHhKSzVyPUCuN\|M6PTFizszN	M2PkcXNCVkeHUh?=
EW-24	NX7OcFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfiW4JZUUN3ME2wMlM{QTh2IN88US=>	M4rlc3NCVkeHUh?=
SF295	M4PnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzLVnJGUUN3ME2wMlM{QTl7IN88US=>	NXXpPYdyW0GQR1XS
MC-IXC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwM{S1JO69VQ>?	NYjYZXFGW0GQR1XS
NCI-H2405	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnDSmZjUUN3ME2wMlM1PzN{IN88US=>	NXSzXWd[W0GQR1XS
NCI-H2009	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwM{S3N\|kh\|ryP	MVjTRW5ITVJ?
LB1047-RCC	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu4TWM2OD1yLkO1PFE2KM7:TR?=	NYHWcXZ4W0GQR1XS
KNS-81-FD	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwM{[2Olch\|ryP	MlzXV2FPT0WU
HOP-92	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVS3bGdZUUN3ME2wMlM3QDNizszN	M4jjOnNCVkeHUh?=
L-428	NWDrb5c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm5TWM2OD1yLkO3NFE3KM7:TR?=	NX;H[FBLW0GQR1XS
C3A	NUToPJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qwTmlEPTB;MD6zO\|M4QSEQvF2=	Mn;NV2FPT0WU
NCI-H1792	NEj5c3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwM{e2OVUh\|ryP	MYnTRW5ITVJ?
HuH-7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPNbnJKSzVyPUCuN\|c6OSEQvF2=	NFjYelBUSU6JRWK=
AGS	NInyfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj1TWM2OD1yLkO4OlM5KM7:TR?=	MVPTRW5ITVJ?
HT-1197	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jLPWlEPTB;MD6zPVQ3KM7:TR?=	NYTHeoxUW0GQR1XS
CGTH-W-1	NX3FZXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PEcWlEPTB;MD6zPVkyOyEQvF2=	NIXCTlFUSU6JRWK=
KNS-42	M3\qUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULCTpBHUUN3ME2wMlQxODR3IN88US=>	MlLWV2FPT0WU
HuO-3N1	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNECwOVUh\|ryP	NWjiXJpWW0GQR1XS
VMRC-RCZ	M2rDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwNECzNFMh\|ryP	NXnjSmFiW0GQR1XS
SW954	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PiUmlEPTB;MD60NFM{PSEQvF2=	MXnTRW5ITVJ?
MES-SA	NUfkWY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwNEC1NFUh\|ryP	NUH3WXdmW0GQR1XS
Ca-Ski	NX\ZWXBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK5eGVWUUN3ME2wMlQxPTJ2IN88US=>	M3zEe3NCVkeHUh?=
SW13	NV;LUpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy5O\|h7UUN3ME2wMlQxPjJ4IN88US=>	NFH6[WtUSU6JRWK=
NCI-H1437	NVrMfnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XlW2lEPTB;MD60NFgxPSEQvF2=	MXPTRW5ITVJ?
U-118-MG	NVXOPYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1juR2lEPTB;MD60NFkxPCEQvF2=	NGXWTmdUSU6JRWK=
NCI-H1734	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwNEKwNVMh\|ryP	NX7MTnVDW0GQR1XS
HDLM-2	NX\TdG5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jER2lEPTB;MD60NlA{OyEQvF2=	MWLTRW5ITVJ?
AU565	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTVTWM2OD1yLkSyOFY5KM7:TR?=	MXfTRW5ITVJ?
FADU	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qyfmlEPTB;MD60NlY1QSEQvF2=	MYjTRW5ITVJ?
OS-RC-2	NYfKeYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHq5SGpKSzVyPUCuOFMxQDNizszN	NIfoeWlUSU6JRWK=
CAMA-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX5RXdGUUN3ME2wMlQ{PjJ4IN88US=>	M33lNnNCVkeHUh?=
MONO-MAC-6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwNEO4OFkh\|ryP	MWDTRW5ITVJ?
LB831-BLC	NF73cFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELwO4tKSzVyPUCuOFQ{PzFizszN	NF;UUW5USU6JRWK=
SW982	NHLKb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnXSmpKSzVyPUCuOFQ2OjhizszN	NVnSepk3W0GQR1XS
SCC-3	NFfRTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zHS2lEPTB;MD60OFU4QSEQvF2=	NIXFNY9USU6JRWK=
C32	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwNEWyNlkh\|ryP	NHHxSXlUSU6JRWK=
BFTC-909	M3vIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rRZmlEPTB;MD60OVI6QSEQvF2=	NX\YXm1YW0GQR1XS
MEG-01	NH7uW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHlcG9KSzVyPUCuOFU{PzNizszN	M4rpT3NCVkeHUh?=
M14	NHGyUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPrTWM2OD1yLkS1PVc6KM7:TR?=	NXvsSJU1W0GQR1XS
MPP-89	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTVTWM2OD1yLkS2NlU3KM7:TR?=	MYfTRW5ITVJ?
HCC1937	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvhTWM2OD1yLkS2N\|g1KM7:TR?=	NGTvXZlUSU6JRWK=
SW837	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjpNHVKSzVyPUCuOFY4OjJizszN	M4\QU3NCVkeHUh?=
DU-145	M4LGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNE[3Nlkh\|ryP	M{H1[3NCVkeHUh?=
LB996-RCC	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4O3WmlEPTB;MD60O\|A2PCEQvF2=	M4P0ZXNCVkeHUh?=
C8166	M{PsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLMbpVyUUN3ME2wMlQ4PCEQvF2=	MXrTRW5ITVJ?
MOLT-4	NWrG[nd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPZTWM2OD1yLkS3O\|M1KM7:TR?=	NV\D[Wt1W0GQR1XS
DMS-53	NVzPeZlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX3TWM2OD1yLkS3PFA6KM7:TR?=	M1TR[HNCVkeHUh?=
TE-5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjKPGE4UUN3ME2wMlQ5OzB3IN88US=>	NFWxOndUSU6JRWK=
KYSE-520	M2HhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;TTWM2OD1yLkS4N\|Q{KM7:TR?=	NFLkRpVUSU6JRWK=
Detroit562	NX\mfYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzWbW9KSzVyPUCuOFg5PiEQvF2=	NF7NWXJUSU6JRWK=
SIMA	M4LEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rScWlEPTB;MD60PVQyPyEQvF2=	MkjmV2FPT0WU
NCI-H1651	NX\lfXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnC[4NKSzVyPUCuOFk3PyEQvF2=	MnPwV2FPT0WU
HCC1599	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwNEm5OVUh\|ryP	NGDaenVUSU6JRWK=
ABC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\oV4ZSUUN3ME2wMlUxPDl4IN88US=>	NHjaUndUSU6JRWK=
CAL-33	NGXJR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwNUC4OFQh\|ryP	NGLQcpJUSU6JRWK=
OPM-2	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNUC5N\|ch\|ryP	MkDxV2FPT0WU
RPMI-7951	M1\Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7wcpNXUUN3ME2wMlUxQTV5IN88US=>	MUHTRW5ITVJ?
HT-1080	NEO0dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHCTWM2OD1yLkWxNVE6KM7:TR?=	NHyzUWJUSU6JRWK=
LC4-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwNUG0NFMh\|ryP	NGDYPJZUSU6JRWK=
OVCAR-3	NWC0[\|BvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwNUG1O{DPxE1?	NXPnWWJ4W0GQR1XS
CAPAN-1	M4e0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;2XINKSzVyPUCuOVIzQDhizszN	NG\O[FNUSU6JRWK=
SK-OV-3	NWGyNFczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Pn[mlEPTB;MD61NlQ{PCEQvF2=	M2rLeXNCVkeHUh?=
HuP-T3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX3VI1OUUN3ME2wMlUzQDJ5IN88US=>	M{XsSXNCVkeHUh?=
NCI-H838	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH2OVhKSzVyPUCuOVI5PDlizszN	MWPTRW5ITVJ?
K5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;qTWM2OD1yLkWzNlAyKM7:TR?=	NXnOO4pmW0GQR1XS
CAL-72	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTpbXlKSzVyPUCuOVM{QDdizszN	NWjxcHh5W0GQR1XS
NH-12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn5TWM2OD1yLkWzPVU6KM7:TR?=	Mn\VV2FPT0WU
SNB75	NHfIeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\6V5NKSzVyPUCuOVU4OyEQvF2=	NFviPFNUSU6JRWK=
BPH-1	Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTJTWM2OD1yLkW2N\|Q1KM7:TR?=	MUTTRW5ITVJ?
NOMO-1	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF6zOmZKSzVyPUCuOVY{PzJizszN	MlnvV2FPT0WU
G-402	NGf3WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfuTWM2OD1yLkW2OFk6KM7:TR?=	NYnQcXN1W0GQR1XS
NCI-H2052	NIfrc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnnOG5KSzVyPUCuOVY4PDFizszN	NW\4WlZ5W0GQR1XS
RCM-1	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTJU41oUUN3ME2wMlU4OTZ4IN88US=>	NHHCOoJUSU6JRWK=
COR-L279	M{fBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHa[2E6UUN3ME2wMlU4OTh3IN88US=>	MXzTRW5ITVJ?
A253	M1;xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULsXGF5UUN3ME2wMlU4PTJ3IN88US=>	NYfle2Q1W0GQR1XS
SK-MM-2	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1qwUmlEPTB;MD61O\|Y4QSEQvF2=	NF;adppUSU6JRWK=
NCI-H1703	NFjMZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwNUm0Nlch\|ryP	MmfBV2FPT0WU
UACC-257	NH7a[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;KRnk{UUN3ME2wMlU6PDh5IN88US=>	M4nwUXNCVkeHUh?=
KALS-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjRWpJKSzVyPUCuOlAxOTFizszN	MXvTRW5ITVJ?
ES5	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETI[YxKSzVyPUCuOlA1QCEQvF2=	MmLuV2FPT0WU
MHH-CALL-2	NWW1VWJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XVU2lEPTB;MD62NFg5QCEQvF2=	MoDhV2FPT0WU
ChaGo-K-1	NUP0W3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHTTWM2OD1yLk[xNlI6KM7:TR?=	M{HwSXNCVkeHUh?=
TGBC1TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\WelhKSzVyPUCuOlE6QCEQvF2=	NE\3XY5USU6JRWK=
KU-19-19	NYG2bG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjhTndXUUN3ME2wMlY1PTh4IN88US=>	NFywUI9USU6JRWK=
COLO-684	NEfscHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\3PWlEPTB;MD62OVYyOSEQvF2=	NVrzN\|hnW0GQR1XS
LS-1034	M3n5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwNkW4NVkh\|ryP	MX\TRW5ITVJ?
RT-112	NUHwcpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml70TWM2OD1yLk[2OVg4KM7:TR?=	NHSzd\|RUSU6JRWK=
Capan-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jCR2lEPTB;MD62OlYzOiEQvF2=	MUfTRW5ITVJ?
HSC-4	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLQUokzUUN3ME2wMlY3Pjl6IN88US=>	M3fze3NCVkeHUh?=
COLO-824	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HleWlEPTB;MD62O\|gzOyEQvF2=	M3nYVnNCVkeHUh?=
NCI-H2170	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\ETWM2OD1yLk[4NlU5KM7:TR?=	Mlq0V2FPT0WU
GDM-1	NYD3ZVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfLc4xKSzVyPUCuOlg1QTRizszN	M1;DN3NCVkeHUh?=
KP-4	NWLCWIFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\0d4ZoUUN3ME2wMlY6PTd\|IN88US=>	MlLZV2FPT0WU
VA-ES-BJ	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfHS2hvUUN3ME2wMlY6QTh4IN88US=>	NIXsdZFUSU6JRWK=
KM-H2	M3rlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{OzTmlEPTB;MD63NFA6OSEQvF2=	NXXQV4sxW0GQR1XS
HH	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwN{C2OlIh\|ryP	M4i2S3NCVkeHUh?=
DK-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;GNJBIUUN3ME2wMlcyODF4IN88US=>	NXzUTnp{W0GQR1XS
VM-CUB-1	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2X1b2lEPTB;MD63NVI2QSEQvF2=	MkPrV2FPT0WU
COLO-829	NVXqUIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3VTWM2OD1yLkexPVg2KM7:TR?=	NFrm[WNUSU6JRWK=
OMC-1	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPETWM2OD1yLkeyNVA1KM7:TR?=	MYnTRW5ITVJ?
NB12	NH;J[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX2NINZUUN3ME2wMlczPTB2IN88US=>	M{jjdXNCVkeHUh?=
NCI-H28	Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfhWo1KSzVyPUCuO\|QxQDNizszN	M2DQUXNCVkeHUh?=
A673	M{PUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwN{WxO\|ch\|ryP	NV:wcXBXW0GQR1XS
LB2241-RCC	NWrXfo82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nQVWlEPTB;MD63OlA5PyEQvF2=	NFS5WYZUSU6JRWK=
CCRF-CEM	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;WNYExUUN3ME2wMlc4ODV{IN88US=>	NXvLbWR[W0GQR1XS
NCI-H510A	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TSSmlEPTB;MD63O\|E5PiEQvF2=	NI\rcFRUSU6JRWK=
SW48	M4rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1voN2lEPTB;MD63O\|M{OyEQvF2=	NH;1NpBUSU6JRWK=
NCI-H2081	NITFPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwN{ixOFch\|ryP	MlHBV2FPT0WU
RMG-I	NXnuWpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrJVVZKSzVyPUCuO\|gzOTJizszN	NHTnVGZUSU6JRWK=
LU-99A	NU[5Z4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwN{i0NVMh\|ryP	NVLGWm85W0GQR1XS
KP-N-YS	NVnGV3RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHKTWM2OD1yLke4PVIyKM7:TR?=	NV\MUIUyW0GQR1XS
MDA-MB-231	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnkTZNNUUN3ME2wMlgxOTNzIN88US=>	NIXYV3NUSU6JRWK=
U031	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLSTWM2OD1yLkixOFI{KM7:TR?=	NVnXSXhJW0GQR1XS
EVSA-T	NEfoTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\ubXJKSzVyPUCuPFE3PzJizszN	MkC0V2FPT0WU
MDA-MB-157	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS1TWM2OD1yLkiyNlcyKM7:TR?=	MYnTRW5ITVJ?
EHEB	M2\TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrXcmZTUUN3ME2wMlgzOjd4IN88US=>	MoC3V2FPT0WU
KINGS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwOEK1OVUh\|ryP	MVXTRW5ITVJ?
23132-87	NILre4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfmTWM2OD1yLkiyPFQ{KM7:TR?=	MV3TRW5ITVJ?
EFO-21	NXP1WIJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwOESwPFkh\|ryP	MUfTRW5ITVJ?
DOK	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjPVlFXUUN3ME2wMlg1QCEQvF2=	MmnJV2FPT0WU
NCI-H2171	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD2cWZYUUN3ME2wMlg1QTZizszN	MVnTRW5ITVJ?
NCI-SNU-5	M2fkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzUWpFKSzVyPUCuPFU2PyEQvF2=	NG[x[2xUSU6JRWK=
SK-N-DZ	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDVTWM2OD1yLki1PVQ{KM7:TR?=	NXHVVpNuW0GQR1XS
SNU-C2B	NF71XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TCVWlEPTB;MD64OlgxOSEQvF2=	M4HG[XNCVkeHUh?=
CP66-MEL	NV36VXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzWWWI4UUN3ME2wMlg4OTFizszN	NF\3fHhUSU6JRWK=
SN12C	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7pTWM2OD1yLki4OlM4KM7:TR?=	M3my[XNCVkeHUh?=
A172	M4PkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HuOWlEPTB;MD64PFY6QCEQvF2=	MkPIV2FPT0WU
NCI-H2347	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwOEi3OVMh\|ryP	NIjkT4pUSU6JRWK=
NCI-H2228	NX;ncJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETKWXVKSzVyPUCuPFk{OzlizszN	MXvTRW5ITVJ?
SNU-387	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrmNGhLUUN3ME2wMlkxOjZ2IN88US=>	NXrwNIpqW0GQR1XS
SK-MEL-24	NHPoTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLVVGdKSzVyPUCuPVE{PDRizszN	MYrTRW5ITVJ?
MDA-MB-468	NXTNbJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHje\|FKSzVyPUCuPVE4OyEQvF2=	NVfXfItuW0GQR1XS
NCI-H1694	NHn5RXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwOUG4O\|Yh\|ryP	MnTsV2FPT0WU
CCF-STTG1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrYTHRDUUN3ME2wMlkzPjN5IN88US=>	NUXHc\|NsW0GQR1XS
K052	NFHmNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkniTWM2OD1yLkm0NFQ4KM7:TR?=	MoXBV2FPT0WU
NCI-H446	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjW[G9KSzVyPUCuPVUxOSEQvF2=	NWXzNGhbW0GQR1XS
MFE-280	M4DCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwOU[yPVEh\|ryP	NIriN5VUSU6JRWK=
KU812	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfiRnRFUUN3ME2wMlk6Ozh7IN88US=>	NHuwTJFUSU6JRWK=
MDA-MB-361	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwOUm3O\|ch\|ryP	MoH4V2FPT0WU
Raji	NU\xdG53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjvNGU{UUN3ME2xMlAzOjZ5IN88US=>	NUO0d5lDW0GQR1XS
TE-6	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwMEO1OlYh\|ryP	MUjTRW5ITVJ?
CAL-148	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTFwMES0OFMh\|ryP	MnTMV2FPT0WU
NCI-H1963	NXvONlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYryfnVEUUN3ME2xMlA1PTV\|IN88US=>	NV23T2xJW0GQR1XS
SK-N-AS	NXm3OJplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnCN25KSzVyPUGuNFQ3QDVizszN	NGfSRlRUSU6JRWK=
RERF-LC-MS	NFLmeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFwME[zOFkh\|ryP	Moj6V2FPT0WU
BEN	NXzmVGgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu3OmlwUUN3ME2xMlA4OTN5IN88US=>	MmDEV2FPT0WU
CAS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnnPWxkUUN3ME2xMlA6OTJ\|IN88US=>	M2q2cHNCVkeHUh?=
SW780	NUfC[\|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPETWM2OD1zLkC5NVgyKM7:TR?=	MYHTRW5ITVJ?
LU-65	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPvTWM2OD1zLkC5OFEh\|ryP	NHHMdVVUSU6JRWK=
D-283MED	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVOwNIp3UUN3ME2xMlEzOjd{IN88US=>	NVTobGNOW0GQR1XS
HCC2157	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{C2SmlEPTB;MT6xN\|Y1OiEQvF2=	MojiV2FPT0WU
RCC10RGB	NWXHfGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjmNmVKSzVyPUGuNVQxODZizszN	M{Xvb3NCVkeHUh?=
PLC-PRF-5	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\sTWM2OD1zLkG1NlI6KM7:TR?=	MojxV2FPT0WU
H4	NF\XS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjENYZKSzVyPUGuNVU1OzlizszN	MkDxV2FPT0WU
TUR	M3zydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoD4TWM2OD1zLkG1O\|UzKM7:TR?=	NX[4T\|QzW0GQR1XS
NCI-H2141	M3i2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;FeVVtUUN3ME2xMlE5QTR4IN88US=>	Mn\ZV2FPT0WU
PFSK-1	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjoPZhKSzVyPUGuNlA2OzJizszN	MlTVV2FPT0WU
SK-MEL-28	M3jwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTFwMkOyNlEh\|ryP	M4\PPHNCVkeHUh?=
SCC-9	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\OZWlEPTB;MT6yN\|Y3PSEQvF2=	NHG3ZXRUSU6JRWK=
T47D	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTFwMkO2PVYh\|ryP	Mnj4V2FPT0WU
TCCSUP	M1PRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j4[WlEPTB;MT6yOVAzQSEQvF2=	NXjEb\|ZbW0GQR1XS
SU-DHL-1	NID5T3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqxbYZKSzVyPUGuNlUyOThizszN	MoDCV2FPT0WU
HL-60	M13ZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwMkW1PFgh\|ryP	M3XhVXNCVkeHUh?=
NCI-H1436	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HsT2lEPTB;MT6yOlE1QSEQvF2=	MnOwV2FPT0WU
DMS-114	NVG4d2RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXpeZhWUUN3ME2xMlI3PjN{IN88US=>	MlHTV2FPT0WU
BOKU	NYnzUINPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDrfZZKSzVyPUGuNlgxQTVizszN	MmLIV2FPT0WU
MS-1	NUDkRmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTzTWM2OD1zLkK5NFY6KM7:TR?=	NWDRUZVEW0GQR1XS
NCI-H661	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwM{C0O\|gh\|ryP	MV7TRW5ITVJ?
HT-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vj[mlEPTB;MT6zNFUzQSEQvF2=	M1vYXnNCVkeHUh?=
CAL-54	M1fudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX3[XpuUUN3ME2xMlMxPzJ3IN88US=>	MkL1V2FPT0WU
SW1463	NUjhT4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwM{G4O\|Ih\|ryP	NGXWNmNUSU6JRWK=
COLO-668	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVO5U3BsUUN3ME2xMlM{ODV4IN88US=>	MkLnV2FPT0WU
PANC-08-13	NHvzcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEe2ZXJKSzVyPUGuN\|M5ODNizszN	MorqV2FPT0WU
BB49-HNC	NHO4T2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jhemlEPTB;MT6zOFAyKM7:TR?=	M2\lbHNCVkeHUh?=
M059J	NULoNnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3wSnU3UUN3ME2xMlM2QDN{IN88US=>	MnnuV2FPT0WU
NCCIT	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny3TWM2OD1zLkO3PVg5KM7:TR?=	NYC5ToxJW0GQR1XS
LN-405	NWi1XW14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXOXoRKSzVyPUGuN\|kzPjRizszN	NWTOUo93W0GQR1XS
UMC-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn2SlZQUUN3ME2xMlM6QTl4IN88US=>	M1\FenNCVkeHUh?=
NB5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLvTWM2OD1zLkSxNlI4KM7:TR?=	M3i3V3NCVkeHUh?=
TE-441-T	NWXSVpUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;SPJJKSzVyPUGuOFI5OTdizszN	M13abnNCVkeHUh?=
ME-180	M1Xs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3DTWM2OD1zLkS0N\|kzKM7:TR?=	NE\EWHFUSU6JRWK=
HCC70	NU[w[5pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HIOGlEPTB;MT60OlA6PiEQvF2=	NGLCflhUSU6JRWK=
no-10	NED4UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjp[JdKSzVyPUGuOFYyQDFizszN	MYLTRW5ITVJ?
JEG-3	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTMSFJFUUN3ME2xMlUxOTN{IN88US=>	MorPV2FPT0WU
no-11	NHr6coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwNUC4PFIh\|ryP	Mk\ZV2FPT0WU
CHP-126	NHfUV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTFwNU[2PVEh\|ryP	MVnTRW5ITVJ?
EGI-1	M{fvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFz5RZNKSzVyPUGuOVgxOjVizszN	NEDXOGFUSU6JRWK=
D-392MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nk[GlEPTB;MT61PVY{KM7:TR?=	NELUdVRUSU6JRWK=
RT4	M33SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;RNVJKSzVyPUGuOVk3OzdizszN	NHnmbW1USU6JRWK=
A204	NVr2ZplVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknDTWM2OD1zLkW5PFAyKM7:TR?=	Mk\2V2FPT0WU
NCI-H1304	NEP6RY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPvfWZyUUN3ME2xMlY{PTlzIN88US=>	M1PpTXNCVkeHUh?=
Becker	M4DWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTFwNkSyOFEh\|ryP	NETCOGpUSU6JRWK=
OE19	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf2TWM2OD1zLk[1OVE5KM7:TR?=	MmrYV2FPT0WU
EKVX	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojQTWM2OD1zLk[1OlE5KM7:TR?=	MX7TRW5ITVJ?
KLE	NUHzeml2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm1WmdKSzVyPUGuOlU4OTRizszN	NI\1SnZUSU6JRWK=
K-562	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPIcZNvUUN3ME2xMlY4ODN5IN88US=>	M{XUNXNCVkeHUh?=
MDA-MB-175-VII	M1zwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1q5bWlEPTB;MT62PFk6PyEQvF2=	MoLVV2FPT0WU
NCI-H716	NYTFN2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvSbY9[UUN3ME2xMlY6OzB2IN88US=>	NY\tWldUW0GQR1XS
Caov-3	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3S5bmlEPTB;MT62PVQyOyEQvF2=	NWLyW2ROW0GQR1XS
HCC1187	NF;KZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrEenlqUUN3ME2xMlcxPTR3IN88US=>	MmLzV2FPT0WU
CAKI-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrYXXlKSzVyPUGuO\|IzQTJizszN	M4jFSXNCVkeHUh?=
MOLT-16	NWK5VWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTFwN{OzNFch\|ryP	M1ntNXNCVkeHUh?=
PC-3	NXfK[JVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj0ZpZmUUN3ME2xMlc2ODhizszN	M4XU[3NCVkeHUh?=
DV-90	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnDcndjUUN3ME2xMlc2PTh3IN88US=>	NF\EVItUSU6JRWK=
RXF393	M3q2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHtUHRKSzVyPUGuO\|czQTRizszN	M1XsfHNCVkeHUh?=
SK-NEP-1	M4f3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfscpZKSzVyPUGuPFI{OzlizszN	MoTjV2FPT0WU
HCC1419	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHITWM2OD1zLkiyOlkzKM7:TR?=	MkXkV2FPT0WU
BV-173	NGnWN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHlTWM2OD1zLkiyPVk2KM7:TR?=	NHjTW21USU6JRWK=
MKN7	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\uNW9KSzVyPUGuPFkzOiEQvF2=	MXfTRW5ITVJ?
LAN-6	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFwOEm1OVMh\|ryP	M2DLTHNCVkeHUh?=
Mo-T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTFwOUCwN\|kh\|ryP	MnrmV2FPT0WU
HCC1395	NVHMT2RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLZbXhkUUN3ME2xMlkzQDZ\|IN88US=>	NEm1SJFUSU6JRWK=
HC-1	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwOUO0O{DPxE1?	M374cHNCVkeHUh?=
HPAF-II	NXO5[pB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwOUS0NVgh\|ryP	MmLqV2FPT0WU
CPC-N	NUjsVndIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\tTWM2OD1zLkm4NFAzKM7:TR?=	NHjsSo9USU6JRWK=
MKN45	NGjDTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFwOUmxNVkh\|ryP	M{DNOXNCVkeHUh?=
NCI-H1693	M{nPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfDTWM2OD1{LkCwOFM{KM7:TR?=	MlrHV2FPT0WU
SHP-77	NYLLOYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXXWXdjUUN3ME2yMlAxPTN\|IN88US=>	NICxPYhUSU6JRWK=
NCI-H1522	NEDXT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7zNI5KSzVyPUKuNFE4OjRizszN	M4joZ3NCVkeHUh?=
SW1573	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi1dZNKSzVyPUKuNFIzKM7:TR?=	NYPkU5lWW0GQR1XS
DBTRG-05MG	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDxTWM2OD1{LkC2NFg4KM7:TR?=	MXrTRW5ITVJ?
SCC-4	NHnpemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPOV25KSzVyPUKuNVQ{OSEQvF2=	NWCySFhFW0GQR1XS
DMS-153	NWXFTlc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV63PZNUUUN3ME2yMlE3PjZ6IN88US=>	MmDLV2FPT0WU
MDA-MB-415	NFjHO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDYdJlKSzVyPUKuNVc2OiEQvF2=	MorOV2FPT0WU
NCI-H2126	M{PqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPlbIZMUUN3ME2yMlIzQDh6IN88US=>	NHS2TJFUSU6JRWK=
MDA-MB-453	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojRTWM2OD1{LkKzN\|Ih\|ryP	M{Py[XNCVkeHUh?=
U-87-MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT1TWM2OD1{LkK4OVkzKM7:TR?=	M1q3S3NCVkeHUh?=
LNCaP-Clone-FGC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HG[GlEPTB;Mj6zNFExOiEQvF2=	M{PSfXNCVkeHUh?=
NCI-H1581	NEP2RlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfKTWM2OD1{LkOyNVA2KM7:TR?=	NGXtbHpUSU6JRWK=
BC-3	NF3welZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTlXFV4UUN3ME2yMlM3PTB7IN88US=>	MnXmV2FPT0WU
HCC38	M2fhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn2xTWM2OD1{LkO4OFQ4KM7:TR?=	MYjTRW5ITVJ?
HCC2218	M2DHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XDVmlEPTB;Mj60NFgxQSEQvF2=	Mlj4V2FPT0WU
RO82-W-1	NEjiSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjrWm5KSzVyPUKuOFEzPSEQvF2=	MVLTRW5ITVJ?
C2BBe1	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37QcGlEPTB;Mj60NVU4QCEQvF2=	MXLTRW5ITVJ?
LAMA-84	NFLnbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH6TWM2OD1{LkW3N\|Y5KM7:TR?=	MoT2V2FPT0WU
GMS-10	MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLpTWM2OD1{LkW3OlEyKM7:TR?=	NV;YVW9XW0GQR1XS
GCT	NHv6do9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\CU2UzUUN3ME2yMlU5Pjl2IN88US=>	MWPTRW5ITVJ?
SK-CO-1	NFHZN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P2OWlEPTB;Mj62NVY3KM7:TR?=	MonHV2FPT0WU
NCI-H526	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37NdmlEPTB;Mj62N\|Q2KM7:TR?=	MXTTRW5ITVJ?
SW1088	M37NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTJwN{e4N\|kh\|ryP	NWDP[m1JW0GQR1XS
HT55	NIfVOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;GfGlEPTB;Mj63PFY6PSEQvF2=	NGT2cGJUSU6JRWK=
NB10	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nzRmlEPTB;Mj64NVc1QCEQvF2=	NHviVI5USU6JRWK=
UACC-893	NH:ySpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTJwOEW3OFkh\|ryP	NWrEN3VrW0GQR1XS
NCI-H1618	NGjaTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;4VGtKSzVyPUKuPFgyPTNizszN	MUDTRW5ITVJ?
NCI-H1092	NEe3Z\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP6c\|dKSzVyPUOuNFc5OTJizszN	NWeweXJEW0GQR1XS
SBC-1	M4HvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnFRndKSzVyPUOuNFg2PTNizszN	NULFNFZKW0GQR1XS
NCI-H1623	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTNwMEmzOEDPxE1?	NF;WWlVUSU6JRWK=
SiHa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DrcmlEPTB;Mz6xNVk4PyEQvF2=	MkfCV2FPT0WU
D-263MG	NX[3elJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrFb5Q2UUN3ME2zMlE1Pzh6IN88US=>	MnvlV2FPT0WU
NCI-H1573	M1jKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfKeY1EUUN3ME2zMlE6PjRzIN88US=>	NEjQR41USU6JRWK=
NCI-H82	M4\6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\DT\|dlUUN3ME2zMlM1PDN7IN88US=>	MlexV2FPT0WU
NCI-H2196	NH\2[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTNwM{WwNFgh\|ryP	NH3B[5pUSU6JRWK=
MFM-223	NYTtOFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOxbZFKSzVyPUOuN\|c{PTFizszN	MoH4V2FPT0WU
COLO-678	NE[y[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPPSIlKSzVyPUOuN\|gyQDZizszN	NIe0NYpUSU6JRWK=
EW-3	M4CwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTNwNEC5OUDPxE1?	NVvCW3VZW0GQR1XS
MHH-NB-11	NWfjU5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTVcIt[UUN3ME2zMlQ1ODZ7IN88US=>	NEG3[mNUSU6JRWK=
EM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{n4cmlEPTB;Mz62N\|k5KM7:TR?=	NVjQOmlPW0GQR1XS
FTC-133	M{DtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFy4c2pKSzVyPUOuOlU1PThizszN	NIPSb3NUSU6JRWK=
NCI-H209	NUDwWGprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXvTWM2OD1\|Lk[3OlU{KM7:TR?=	M3K5[HNCVkeHUh?=
TGBC24TKB	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXMV4RKSzVyPUOuOlg{PTVizszN	MknQV2FPT0WU
LC-1F	NWTMU2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorDTWM2OD1\|LkexO\|Y1KM7:TR?=	MonIV2FPT0WU
C-4-II	NX;hT2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLMb2hKSzVyPUOuO\|U3PDNizszN	MVfTRW5ITVJ?
NCI-H1650	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nyOWlEPTB;Mz63PFQ2PSEQvF2=	M1rCdXNCVkeHUh?=
JVM-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37oUmlEPTB;Mz65N\|Y{QSEQvF2=	NGP1SoVUSU6JRWK=
CaR-1	NXXubXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DBNmlEPTB;Mz65O\|YyPyEQvF2=	NW\lXnZuW0GQR1XS
MDA-MB-134-VI	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLPTWM2OD12LkCyPVUzKM7:TR?=	M{fPbnNCVkeHUh?=
NCI-H719	NXrXSFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYraXVR1UUN3ME20MlE2Ozh6IN88US=>	Ml:yV2FPT0WU
GOTO	M{fzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLWVFNkUUN3ME20MlI6PzB3IN88US=>	M4nrU3NCVkeHUh?=
NCI-N87	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jxbmlEPTB;ND6zPFgzOSEQvF2=	M1:1NXNCVkeHUh?=
NB6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVX4ToFCUUN3ME20MlQzPTB7IN88US=>	MUfTRW5ITVJ?
DSH1	NVW4ZYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILScXdKSzVyPUSuOFcyOTZizszN	NEW1THZUSU6JRWK=
BT-20	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\jTWM2OD12LkS5NFAzKM7:TR?=	M1fEOXNCVkeHUh?=
NCI-H1882	NV[yTndJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrKTWM2OD12LkWwOVch\|ryP	NIH3eodUSU6JRWK=
WM-115	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTRwNUC4PFEh\|ryP	MWPTRW5ITVJ?
SKG-IIIa	NEfuTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrDcWZOUUN3ME20MlY4PzdizszN	NUjwU\|JXW0GQR1XS
NCI-H69	M2C1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTRwN{CyO\|Uh\|ryP	Mlr4V2FPT0WU
MSTO-211H	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHaTWM2OD12LkizOVY2KM7:TR?=	M2TzOXNCVkeHUh?=
Mewo	NHjWV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTRwOU[zNVMh\|ryP	NX7J[XNjW0GQR1XS
GI-ME-N	NXH1[JU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TVTmlEPTB;NT6wNFUxQSEQvF2=	NF:yOWxUSU6JRWK=
T98G	NHf6U4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUC2U2hOUUN3ME21MlA3PTB6IN88US=>	Mn3sV2FPT0WU
ECC4	NHPzeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOwTWM2OD13LkC5N\|czKM7:TR?=	NIrGOXRUSU6JRWK=
EW-11	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTVwMUiwPVkh\|ryP	MXvTRW5ITVJ?
COLO-800	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLne\|FiUUN3ME21MlE6OzR7IN88US=>	MXfTRW5ITVJ?
NCI-H1755	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTVwMkOwNlch\|ryP	M4HReHNCVkeHUh?=
KMS-12-PE	NF3CNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDzTWM2OD13LkO1NFg2KM7:TR?=	M3GzRnNCVkeHUh?=
HCC1954	NEjXSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTVwOEW5O\|Eh\|ryP	M{i1[3NCVkeHUh?=
NCI-H187	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm1[nY{UUN3ME21MlkzQTh7IN88US=>	MkHWV2FPT0WU
LU-165	NYDmcm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TCSWlEPTB;NT65PVAxOiEQvF2=	NWPZNnBJW0GQR1XS
YAPC	NUHveoZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[2fmlEPTB;NT65PVA3QCEQvF2=	NUPLNG4{W0GQR1XS
LU-139	NFTETI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXEW49KSzVyPU[uNFg{PjhizszN	MmPoV2FPT0WU
D-502MG	M4jBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;KTWM2OD14LkOyNFQ4KM7:TR?=	MUfTRW5ITVJ?
IST-SL1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLGTWM2OD14LkWzPVQ5KM7:TR?=	M4qz[3NCVkeHUh?=
DG-75	NFLnSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrC[GpwUUN3ME22Mlg5Pzh4IN88US=>	NH62eHBUSU6JRWK=
NCI-H1155	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPsXGNKSzVyPU[uPVU2QDFizszN	NEnTVIpUSU6JRWK=
EFE-184	M4jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTsTWM2OD15LkOxOlk2KM7:TR?=	NYDrSodSW0GQR1XS
AsPC-1	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHOWFl7UUN3ME23MlQ5QDB5IN88US=>	MmjEV2FPT0WU
SW948	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y0PWlEPTB;Nz61PFM6PSEQvF2=	M4nHTXNCVkeHUh?=
NCI-H524	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTlwNUi2Nlgh\|ryP	MmK3V2FPT0WU
KOSC-2	NHGxTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HtVmlEPTB;OT62Nlg{PCEQvF2=	NVTNT4hwW0GQR1XS
T-24	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfjdYtKSzVyPUmuPVQ1OTVizszN	MUXTRW5ITVJ?
NCI-H748	M3vycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[5W\|RbUUN3ME2xNE43Ozl5IN88US=>	MXzTRW5ITVJ?
NCI-H23	M4XFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDRPHpYUUN3ME2xNE43PDR{IN88US=>	NVfwfXFsW0GQR1XS
UACC-812	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYKwcJhzUUN3ME2xNU44OTdizszN	M1n6fnNCVkeHUh?=
SCLC-21H	NWS2[WtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTF{LkG1OVEh\|ryP	NEfibJNUSU6JRWK=
NCI-SNU-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTYTWM2OD1zMz6xNlU5KM7:TR?=	NWXPcJlNW0GQR1XS
HD-MY-Z	NY\kVGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTF2Lk[zOlMh\|ryP	NVfSUYw3W0GQR1XS
SK-N-FI	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nTNmlEPTB;MUSuPFkyOiEQvF2=	NWjUfIdmW0GQR1XS
LB647-SCLC	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTF3LkexPVUh\|ryP	M1LnS3NCVkeHUh?=
NCI-H345	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jvfGlEPTB;MUeuN\|Q{KM7:TR?=	MXLTRW5ITVJ?
NCI-H1563	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTF6Lke2NFEh\|ryP	MX3TRW5ITVJ?
RL	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJzLkK2OVYh\|ryP	NH64UW1USU6JRWK=
KY821	NX3SOmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETvUWNKSzVyPUKyMlA2PTNizszN	NXjLeWJOW0GQR1XS
JVM-3	NGX5UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPKeVcxUUN3ME2yOU4xPDF\|IN88US=>	MV3TRW5ITVJ?
NCI-H1793	M3PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XheWlEPTB;MkiuOVQ6QSEQvF2=	NWjhRVBZW0GQR1XS
LU-134-A	NY\INZdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTNyLkKwN\|ch\|ryP	M2TXR3NCVkeHUh?=
NCI-H1395	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\1NotvUUN3ME2zNk4zPDNzIN88US=>	M3PSfHNCVkeHUh?=
NCI-H1993	NGHJcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTN{LkiyNVgh\|ryP	MkPjV2FPT0WU
P31-FUJ	M3PhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{WxXWlEPTB;M{OuOFg6QSEQvF2=	MnvhV2FPT0WU
LS-513	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\KdWlEPTB;M{WuPFg4QSEQvF2=	NIrsUFBUSU6JRWK=
SK-MEL-1	M3;DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTRyLkO0PVkh\|ryP	MXPTRW5ITVJ?
SW684	NGLqVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYX6cZpwUUN3ME20N{46PjZzIN88US=>	NHfzTZpUSU6JRWK=
COR-L88	M1\idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG2TWM2OD12ND6wOlY2KM7:TR?=	M{fFb3NCVkeHUh?=
NCI-H889	M2\Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TTdmlEPTB;NEWuNFA5PyEQvF2=	NVfaW\|VqW0GQR1XS
TALL-1	NHfGZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwVWpKSzVyPUS2MlEyQTlizszN	MnLNV2FPT0WU
KARPAS-299	M3jmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK5ZopKSzVyPUS3MlE6QTNizszN	Mn;1V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT00918931	Terminated	Leukemia\|Systemic Mastocytosis	M.D. Anderson Cancer Center\|Gemin X	June 2009	Phase 2
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 28 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 28 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)